Shreehas Tambe appointed as MD & CEO of Biocon Biologics
Tambe has taken over from Arun Chandavarkar, who continues to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics
Source: businesstoday.in
📰 Biocon Ltd News
Page 32 - Biocon Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Biocon Ltd. Real-time updates on events, politics, business and more.
Global Diabetes Insulin Delivery Pen Market 2022-2028: Focus on United States, UK, Canada France, Italy, Spain, Germany, Netherlands, Poland, Sweden, Turkey, Australia, Japan, China, India, & Brazil
/PRNewswire/ -- The "Global Diabetes Insulin Delivery Pen Market 2022: Insights, Trends, Competition, Growth Opportunities, Market Size, Market Share Data,...
Source: prnewswire.com
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
Biocon Biologics Ltd., a subsidiary of Biocon Ltd, announced today that it has successfully completed its multi-billion-dollar acquisition of the global biosimilars business of its partner Viatris Inc.
Kiran Mazumdar Shaw Robertj Coury Rajiv Malik Biocon Biologics Serum Institute Life Sciences Biocon Biologics Ltd
Source: equitybulls.com
Biocon Biologics completes acquisition of Viatris Inc
Biocon Biologics Ltd, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday announced the completion of its acquisition of global biosimilars business of its partner Nasdaq listed Viatris Inc.Biocon Biologics and Viatris have ...
Tamil Nadu Kiran Mazumdar Shaw Rajiv Malik Biocon Biologics Serum Institute Life Sciences Biocon Biologics Ltd
Source: prokerala.com
Latest News | Biocon Biologics Completes Acquisition of Viatris' Global Biosimilars Biz
Get latest articles and stories on Latest News at LatestLY. Biocon on Tuesday said its unit Biocon Biologics has completed the multi-billion dollar acquisition of the global biosimilars business of its partner Viatris Inc. Latest News | Biocon Biologics Completes Acquisition of Viatris Global Biosimilars Biz.
New Delhi Kiran Mazumdar Shaw Rajiv Malik Biocon Biologics Serum Institute Life Sciences Competition Commission Of India
Source: latestly.com
Biocon subsidiary completes acquisition of Viatris for USD 3 billion
Biocon Biologics, a subsidiary of listed biopharmaceutical company Biocon Ltd, on Tuesday announced that it has successfully completed its acquisition of the global biosimilars business of its partner Viatris for USD 3 billion.
Kiran Mazumdar Shaw Biocon Biologics Serum Institute Life Sciences Competition Commission Of India Biocon Ltd Us Federal Trade Commission
Source: webindia123.com
World News | Biocon Subsidiary Completes Acquisition of Viatris for USD 3 Billion
Get latest articles and stories on World at LatestLY. According to a statement by the pharma company, Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors, respectively. World News | Biocon Subsidiary Completes Acquisition of Viatris for USD 3 Billion.
Qamar Javed Bajwa Kiran Mazumdar Shaw Biocon Biologics Serum Institute Life Sciences Read Pakistan Army Reputation Saw Decline Competition Commission Of India
Source: latestly.com
Active Pharmaceutical Ingredients (API) Market is Expected to Grow to a Value of US$ 331.3 Bn by 2031
Active Pharmaceutical Ingredients [API] Market is Expected to Grow to a Value of US$ 331.3 Bn by 2031 | Transparency Market Research
Source: sandiegosun.com
The Worldwide Smart Insulin Pens & Pumps Industry is Expected to Reach $478 Million by 2027: Increasing Awareness of Diabetic Management Tools is Driving Growth
The "Global Smart Insulin Pens & Pumps Market (2022-2027) by Products, End-Users, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff
Source: einnews.com
Latest News | Biocon Biologics Allots Equity Shares Worth Rs 2,205.63 Crore to Its Parent
Get latest articles and stories on Latest News at LatestLY. Biotechnology major Biocon on Thursday said its subsidiary Biocon Biologics has allotted equity shares worth Rs 2,205.63 crore to it as part of an equity infusion to fund the latters acquisition of Viatris Incs biosimilars business. Latest News | Biocon Biologics Allots Equity Shares Worth Rs 2,205.63 Crore to Its Parent.
Source: latestly.com